Chronic bronchiectatic lung diseases affect an estimated 500,000 adults in the US — and despite decades of treatment, available therapies don’t stop them from progressing. The reason: current treatments address the symptoms. None targets the source.

Clarametyx is changing that. 

Bronchiectasis is a condition in which the bronchi — the airways that carry air in and out of the lungs — become damaged and widened, impairing the ability to clear mucus and trapping bacteria. Over time, this cycle of infection and inflammation causes progressive damage and loss of lung function.

In progressive lung diseases such as cystic fibrosis and non-CF bronchiectasis, infection, inflammation and structural lung damage build on each other. Impaired pathogen clearance allows bacteria to persist in the airways, driving chronic inflammation that damages and widens bronchial walls — leading to further impairment, worsening infection, and progressive, irreversible loss of lung function.

This self-perpetuating cycle, known as the vicious vortex, makes these diseases progressively harder to control. Current treatments only target downstream symptoms, without changing the course of the disease.

In many patients, the central upstream driver is bacterial biofilm. That is what Clarametyx technology is designed to disrupt.

Many disease-causing bacteria naturally form biofilm communities that are inherently pro-inflammatory and highly resistant to immune attack. These biofilms are composed of: 

• extracellular polymeric substance (EPS) 
• a scaffolding matrix of extracellular DNA (eDNA) and “linchpin” (red) binding proteins

Biofilms are implicated in approximately 80% of chronic bacterial infections and are a central inflammatory driver in most chronic and progressive respiratory diseases.

Clarametyx has developed a novel upstream approach that addresses multiple drivers of lung decline. Unlike current therapies, CMTX-101 disrupts chronic respiratory disease at the source. By targeting the bacterial biofilm — the primary upstream driver of the inflammatory cascade — we stop the cycle of exacerbations and lung decline at the root, delivering a true disease-modifying solution. 

Primary goals:

1. Preserve lung function by disrupting the cycle of progressive inflammation, damage and dysfunction associated with chronic respiratory disorders 
2. Restore the immune system’s ability to efficiently clear a broad range of disease-causing respiratory bacteria

Clarametyx technology targets DNABII, a universal connector protein in the biofilm structure.  

• CMTX-101 (blue) antibodies capture and remove key linchpin proteins (red), resulting in rapid biofilm collapse
• Can be applied regardless of the bacteria present in the biofilm

CMTX-101 has demonstrated clinical proof of concept in cystic fibrosis and is advancing into a Phase 2 bronchiectasis study planned for 1H27.